1-3 of 3
Kantharaj Ethirajulu
Close
Sort by
Journal Articles

Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies

Guillermo Garcia-Manero, MD, Charles Chuah, MBChB, FRCPE, MD, George Wilding, Julie Chang, MD, Srdan Verstovsek, MD, PhD, Stefan Faderl, MD, Hagop M. Kantarjian, MD, Kantharaj Ethirajulu, Joy Zhu
Journal: Blood
Blood (2010) 116 (21): 3292.
https://doi.org/10.1182/blood.V116.21.3292.3292
Published: 2010
Journal Articles

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Srdan Verstovsek, MD, PhD, Olatoyosi Odenike, MD, Bart Scott, MD, Zeev Estrov, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Ann Lowe, MD, Huan J. Zhu, MD, PhD, Hagop Kantarjian, MD, H. Joachim Deeg, MD
Journal: Blood
Blood (2009) 114 (22): 3905.
https://doi.org/10.1182/blood.V114.22.3905.3905
Published: 2009
Journal Articles

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, MD, Michelle Fanale, M.D., Peter McLaughlin, Amanda R Copeland, MS, Silvana de Castro Faria, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Huan J. Zhu, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 588.
https://doi.org/10.1182/blood.V114.22.588.588
Published: 2009